文献速递脑血管病

COOLIST试验:缺血性卒中低温治疗的多中心开放随机II期临床研究

COOLIST (Cooling for Ischemic Stroke Trial): A Multicenter, Open, Randomized, Phase II, Clinical Trial.
PubMed 文献 · Stroke · 2016-11-17

本研究为多中心开放随机II期临床试验,比较清醒急性缺血性卒中患者(NIHSS≥6,发病4.5小时内)标准治疗与表面低温至34.0°C、34.5°C或35.0°C的可行性和安全性。因招募缓慢在22例后终止,仅35.0°C组可行,低温组肺炎风险增加。

要点

  • 表面低温至35.0°C在清醒缺血性卒中患者中可行,但34.5°C和34.0°C不可行。
  • 低温治疗与肺炎风险增加相关(绝对风险增加53%,95%CI 28-79%)。
  • 研究因招募缓慢提前终止,样本量小(22例),结果需谨慎解读。

核心结论

  • 在清醒急性缺血性卒中患者中,表面低温至35.0°C可行,但34.5°C和34.0°C不可行。
  • 低温治疗与肺炎风险增加相关。

研究设计与样本

  • 多中心、随机、开放、II期临床试验,比较标准治疗与表面低温至34.0°C、34.5°C或35.0°C。
  • 纳入清醒急性缺血性卒中患者,NIHSS评分≥6,症状发作4.5小时内开始低温并维持24小时。
  • 因招募缓慢在22例患者后终止入组。

主要发现

  • 34.0°C组5例、34.5°C组6例、35.0°C组5例(其中4例开始低温)、标准治疗组6例。
  • 完成指定治疗的患者比例:34.0°C组0%(0例)、34.5°C组17%(1例)、35.0°C组75%(3例),P=0.03。
  • 达到目标体温的患者比例:34.0°C组0%(0例)、34.5°C组33%(2例)、35.0°C组100%(4例),P=0.01。
  • 肺炎在8例低温患者中发生,对照组无发生(绝对风险增加53%,95%CI 28-79%,P=0.002)。

临床怎么用

  • 对于清醒急性缺血性卒中患者,表面低温至35.0°C可能可行,但需警惕肺炎风险。
  • 34.5°C和34.0°C的表面低温在清醒患者中不可行,不宜常规尝试。

局限性

  • 研究因招募缓慢提前终止,样本量小(22例),统计效力有限。
  • 开放标签设计可能引入偏倚。
  • 可行性主要终点定义以及部分组别低温未启动可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Animal studies suggest that cooling improves outcome after ischemic stroke. We assessed the feasibility and safety of surface cooling to different target temperatures in awake patients with acute ischemic stroke. METHODS: A multicenter, randomized, open, phase II, clinical trial, comparing standard treatment with surface cooling to 34.0°C, 34.5°C, or 35.0°C in awake patients with acute ischemic stroke and an National Institutes of Health Stroke Scale score of ≥6, initiated within 4.5 hours after symptom onset and maintained for 24 hours. The primary outcome was feasibility, defined as the proportion of patients who had successfully completed the assigned treatment. Safety was a secondary outcome. RESULTS: Inclusion was terminated after 22 patients because of slow recruitment. Five patients were randomized to 34.0°C, 6 to 34.5°C, 5 to 35.0°C (cooling was initiated in 4), and 6 to standard care. No (0%), 1 (17%), and 3 (75%) patients, respectively, completed the assigned treatment (P=0.03). No (0%), 2 (33%), and 4 (100%) patients reached the target temperature (P=0.01). Pneumonia occurred in 8 cooled patients but not in controls (absolute risk increase, 53%; 95% confidence interval, 28-79%; P=0.002). CONCLUSIONS: In awake patients with acute ischemic stroke, surface cooling is feasible to 35.0°C, but not to 34.5°C and 34.0°C. Cooling is associated with an increased risk of pneumonia. CLINICAL TRIAL REGISTRATION: URL: http://www.trialregister.nl. Unique identifier: NTR2616.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Geurts M, Petersson J, Brizzi M, et al. COOLIST (Cooling for Ischemic Stroke Trial): A Multicenter, Open, Randomized, Phase II, Clinical Trial. Stroke. 2016. PMID: 27856954. doi:10.1161/STROKEAHA.116.014757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。